Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

Capricor Therapeutics, Inc. (CAPR) has disclosed a new risk, in the Sales & Marketing category.

Capricor Therapeutics, Inc. could become highly dependent on Nippon Shinyaku for the commercialization of Deramiocel in the United States and Japan, with its future revenue stream tied to milestones and revenue‑sharing under long‑term, hard‑to‑terminate distribution agreements. If Nippon Shinyaku, or any future distribution partner, deprioritizes, underfunds, or otherwise fails to effectively commercialize Deramiocel, the company’s revenue potential, financial condition, and operating results could be materially constrained.

The average CAPR stock price target is $54.50, implying 82.82% upside potential.

To learn more about Capricor Therapeutics, Inc.’s risk factors, click here.